AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 22 min read$LLY

Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?

Eli Lilly (LLY) reported Q3 revenue of $24.4B, up 39% YoY, driven by GLP-1 products Mounjaro and Zepbound. Earnings per share rose 7% to $7.48. The company raised its 2026 revenue guidance to $91B-$92B. Growth was fueled by strong sales of key drugs and a diversified pipeline, despite pricing pressures and potential competition.

Original reporting
finance.yahoo.com
Published Nov 2, 2026, 6:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 7:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to drive short‑term buying pressure, though long‑term risks remain from competition.

02

Market read

Earnings beat and guidance raise make the stock a near‑term buying candidate.

03

What to watch

Rising competition in obesity drugs and possible regulatory scrutiny on pricing.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

Eli Lilly's Q3 update highlights continued dominance of its GLP‑1 portfolio and a significant guidance upgrade.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly reported Q3 results with revenue up 39% YoY to $24.4B and raised FY2026 revenue guidance to $91‑92B.

Expected impact

likely upward pressure as market prices in the revenue beat and guidance raise

Evidence & confidence

Revenue and earnings beat expectations; guidance increase signals continued growth, prompting buying interest.

Market effects

Sector

Positive for the broader pharma/biotech sector as GLP‑1 growth continues.

Regional

U.S. market may see modest lift in healthcare indices.

Global

Reinforces global interest in obesity/diabetes therapeutics.

Counterpoint

What could challenge this read

Potential pricing pressure on GLP‑1 products could curb future growth.

Key entities

  • Company
    Eli Lilly

    Pharmaceutical company reporting Q3 results.

Read at source← All news

StoryEli Lilly posts Q3 2026 beat, lifts FY 2026 revenue outlook to $91‑$92 B, trims EPS guidance to $35‑$36

Also covered by

4 outlets

Related articles

NOV 2
$MRKMed

Western Pharma Giants Paid Millions to Russian Distributors Linked to Fraud, Whistleblower Report Says

Merck, Eli Lilly, Novartis, and AstraZeneca allegedly paid high bonuses to Russian distributors, enabling a corruption scheme in Russia's healthcare system, according to a whistleblower report. The report claims excessive rebates and non-competitive practices, with Merck's R-Pharma winning most bids for Keytruda. The companies either declined or did not respond to comments.

themoscowtimes.com3 min
NOV 2
$LLYMed

Musk Predicts “Banger Drugs Coming Out” from Eli Lilly

Eli Lilly raised its 2026 revenue guidance to $91-92B, driven by Mounjaro and Zepbound, which accounted for 65% of H1 2026 revenue. CEO Dave Ricks responded to Elon Musk's X post endorsing Lilly's drug pipeline. Retatrutide, a key pipeline drug, faces FDA classification challenges. Lilly's stock traded at 34x forward earnings before the earnings rally.

finance.yahoo.com6 min
NOV 2
$LLYMedAI 9/10

When Eli Lilly's Forecast and Chart Say the Same Thing, Pay Attention

Eli Lilly (LLY) raised its 2026 revenue forecast to $91B-$92B, up 6.4% from prior, citing strong portfolio performance. Q3 revenue from Mounjaro and Zepbound exceeded $16B. Earnings forecast was cut to $35-$36 per share. The stock gained 10% over two days, outperforming the S&P 500. The stock is 18.4% above its 50-day average and 30.1% above its 200-day average.

finance.yahoo.com2 min
NOV 2
$LLYMed

What Has Changed About Owning Eli Lilly Stock?

Eli Lilly (LLY) reported a 75.3% return over the past year, outperforming the S&P 500. Its Q3 2026 report showed a shift in spending, with $19.0B on capital projects exceeding $15.4B on R&D for the year. This marks the first time since 2011 that capital spending surpassed research. The company is investing in new manufacturing sites, including a $6.5B facility in Houston, to support growth of drugs like Mounjaro and Zepbound, which generated over $16B in Q3 revenue.

finance.yahoo.com2 min
NOV 2
$MRKMed

Pharma giants pay millions to Russian distributor entangled in corruption allegations to win cancer drug business

Merck, Eli Lilly, Novartis, and AstraZeneca allegedly paid millions in bonuses to Russian distributors, including R-Pharm, which faces corruption allegations. Whistleblower reports claim these payments may have facilitated kickbacks to officials for cancer drug contracts, potentially violating the U.S. Foreign Corrupt Practices Act. The companies have not publicly addressed the allegations.

icij.org3 min